Several possible studies
Story checked
What to know about the GLP-1 injections recall (opens in a new tab)
nypost.com · 2026-10-20
Short answer
Several possible studiesNo confirmed study match.
Several papers could fit this story, but none could be confirmed as its source. The claims remain unverified.
These papers were considered as possible sources, but none could be confirmed as the study behind this story.
Share this check
The story
What to know about the GLP-1 injections recall
nypost.com · 2026-10-20
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Source layer
The 3 papers the story cites
Source study separated from background citations.
The research anchor for the report.
- Points somewhere elsepresented as the new finding
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=99952
- Cited as backgroundpresented as earlier work
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/apothecary-pharma-llc-717972-12012025
- Cited as backgroundpresented as earlier work
https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 7Not checkedThe FDA has recalled a popular weight-loss shot across the country because of potential contamination.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 7Not checkedApothecary Pharma is recalling 22 vials of compounded tirzepatide, the active ingredient in Mounjaro and Zepbound, while the brand-name drugs are not affected.View evidenceHide evidence
As stated22 vials
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 7Not checkedApothecary Pharma is also recalling a NAD+ injection for possible contamination.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 7Not checkedBoth recalls are Class II, meaning use could cause temporary or medically reversible adverse health consequences, though severe health consequences are unlikely.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 7Not checkedThe FDA had already issued a warning letter to Apothecary Pharma after finding serious deficiencies in sterile drug उत्पादन practices and concerns about contamination risk.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 6 of 7Not checkedThe article says the FDA has broader concerns about compounded GLP-1 drugs, including dosing errors that led to hospitalizations, storage problems, and fraudulent products.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 7 of 7Not checkedThe FDA has received more than 730 reports of bad reactions to compounded tirzepatide, though it says this is likely underreported.View evidenceHide evidence
As statedmore than 730 reports
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.
Search results
Candidate papers, not confirmed sources.
PubMed, Europe PMC, Crossref · 15 candidate papers
Improving Medication Classification in GLP-1RA Research: Feasibility of a Photo-Review Protocol.
Obesity Science & Practice · 2026 · PubMed, Europe PMC
Same Result, Different Price: Compounded versus Branded Tirzepatide
2026 · Crossref
Unregulated Peptide Use in the Age of Biohacking: Digital Promotion, Gray-Market Access, and Emerging Public Health Risks.
2026 · Europe PMC
Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs.
Missouri Medicine · 2026 · PubMed
Compounded bioidentical menopausal hormone therapy
Fertility and Sterility · 2012 · Crossref